Laura E. Niklason - 16 Nov 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Reporting relationship: President, CEO and Director, Director
Issuer ticker: HUMA
Reported as of: 16 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Nov 2025, 17:48:26 UTC
Prior SEC filing: 20 Aug 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact

Key filing fact

Laura E. Niklason filed Form 4 for Humacyte, Inc. (HUMA) on 17 Nov 2025.

Key facts

This page summarizes Laura E. Niklason's Form 4 filing for Humacyte, Inc. (HUMA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Nov 2025, 17:48.

Change

Previous filing in this sequence was filed on 20 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001878075 Primary reporting owner

Niklason Laura E

Relationship: President, CEO and Director, Director
Address: 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Signature date: 17 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HUMA transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $0
Shares: +311,100
Change %
Price: $0.000000
Shares after: 311,100
Date: 16 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 311,100
Exercise price: $1.23
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.